Skip to main content
Fig. 1 | BMC Women's Health

Fig. 1

From: The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis

Fig. 1

Pooled median progression-free survival A and overall survival B by residual disease status across studies. N numbers represent number of data points used in analysis. Median progression-free survival per residual disease status was reported in 12 studies and median overall survival per residual disease status was reported in 27 studies. Residual disease > 1 cm category includes studies reporting residual disease 1–2 cm and residual disease > 1 cm. CI, confidence interval

Back to article page